Landmark trial
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp R, Mason WP, van den Bent MJ, et al. · EORTC / NCIC
DoseLab summary
Phase 3 trial showing that temozolomide given with and after radiotherapy (60 Gy in 30 fractions) improved survival in glioblastoma compared with radiotherapy alone. Citation checked against Crossref.
Why this is useful
The trial behind the standard 60 Gy in 30 fractions with temozolomide.
Reference details
- Title
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
- Authors / organization
- Stupp R, Mason WP, van den Bent MJ, et al. · EORTC / NCIC
- Publication / protocol
- N Engl J Med. 2005;352(10):987–996
- Version
- Pending verification
- Year
- 2005
- DOI
- 10.1056/NEJMoa043330
- Disease sites
- CNS / Brain
- Topics
- Glioma, Glioblastoma, Chemoradiation, Landmark trial
- Fractionation context
- 60 Gy / 30 fx
- Last reviewed by DoseLab
- Pending verification